Carlsmed (NASDAQ:CARL) Shares Gap Up After Strong Earnings

Carlsmed, Inc. (NASDAQ:CARL – Get Free Report) shares gapped up prior to trading on Wednesday following a better than expected earnings announcement. The stock had previously closed at $14.71, but opened at $16.00. Carlsmed shares last traded at $18.4330, with a volume of 414,094 shares changing hands.

The company reported ($0.34) EPS for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.08. Carlsmed had a negative net margin of 55.82% and a negative return on equity of 42.42%. The business had revenue of $21.55 million during the quarter.

Recent Carlsmed Headlines

Investors following CARL have been watching these headlines:

  • Positive Sentiment: Carlsmed reported third-quarter 2026 EPS of -$0.34, better than the consensus estimate of -$0.42, and revenue of $21.55 million. The company also expects 2026 revenue of $78 million to $80 million, citing new DRG tailwinds and product launches planned for the fourth quarter. Carlsmed third-quarter results Revenue outlook and product launches
  • Positive Sentiment: Analysts raised their price targets after the results while maintaining Buy ratings: BTIG lifted its target to $26, Truist to $23, and Needham to $22 from $17. These revisions signal improved analyst expectations for CARL. Analyst forecast revisions Needham price target update
  • Neutral Sentiment: CARL was among healthcare and biotech stocks moving higher, suggesting sector-wide strength may also have contributed to its recent momentum, beyond the company’s earnings news. Biotech and healthcare stocks move higher

Wall Street Analyst Weigh In

CARL has been the subject of a number of research analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Carlsmed in a report on Wednesday, November 4th. BTIG Research raised their target price on Carlsmed from $24.00 to $26.00 and gave the company a “buy” rating in a research report on Wednesday. Needham & Company LLC lifted their price target on Carlsmed from $17.00 to $22.00 and gave the stock a “buy” rating in a research note on Wednesday. Wall Street Zen raised Carlsmed from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Finally, Truist Financial boosted their price target on Carlsmed from $20.00 to $23.00 and gave the stock a “buy” rating in a research report on Wednesday. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Carlsmed has a consensus rating of “Moderate Buy” and an average price target of $22.00.

View Our Latest Stock Analysis on CARL

Hedge Funds Weigh In On Carlsmed

Several hedge funds and other institutional investors have recently modified their holdings of CARL. BlackRock Inc. purchased a new stake in Carlsmed during the 2nd quarter valued at about $5,528,000. Janus Henderson Group PLC raised its holdings in Carlsmed by 7.6% in the 1st quarter. Janus Henderson Group PLC now owns 1,227,452 shares of the company’s stock valued at $11,108,000 after acquiring an additional 86,834 shares during the last quarter. KCM Capital Inc purchased a new position in Carlsmed in the 1st quarter worth approximately $1,810,000. Parkman Healthcare Partners LLC purchased a new position in Carlsmed in the 2nd quarter worth approximately $6,200,000. Finally, Jupiter Topco LLC purchased a new position in Carlsmed in the 2nd quarter worth approximately $12,992,000.

Carlsmed Stock Performance

The company has a fifty day moving average price of $14.93 and a two-hundred day moving average price of $12.56. The company has a current ratio of 5.79, a quick ratio of 8.66 and a debt-to-equity ratio of 0.20.

About Carlsmed

(Get Free Report)

Carlsmed, Inc. is a medical technology company focused on personalized solutions for spine surgery. Its technology uses patient-specific planning and implant design to help surgeons plan spinal-fusion procedures. The company’s products include aprevo®, a line of patient-specific interbody implants made using 3D printing. Carlsmed’s platform is designed to use a patient’s imaging and surgical plan to tailor implant geometry and support alignment goals. Founded in 2018 and based in Carlsbad, California, Carlsmed serves the U.S. market.

Further Reading

Receive News & Ratings for Carlsmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Carlsmed and related companies with MarketBeat.com's FREE daily email newsletter.